JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY is an esteemed publication dedicated to the fields of Immunology and Allergy, published by ESMON PUBLICIDAD S A in collaboration with the Department of Allergy and Clinical Immunology at the University Clinical Navarra, Spain. With its rich history spanning over three decades since its inception in 1991, this journal has gained prominence in the scientific community, holding a commendable Q2 quartile in Allergy and a Q3 quartile in Immunology. Ranked within the top tiers of its categories according to Scopus, it stands at Rank #80/233 in Immunology and Allergy, and Rank #96/236 in Immunology and Microbiology, indicating its influential role in disseminating cutting-edge research and clinical insights. Though primarily print-focused, the journal strives to bridge gaps in knowledge and contribute to the ongoing dialogue among researchers, professionals, and students in the immunological sciences. The JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY is essential for anyone committed to advancing the understanding of allergic and immunological conditions.

ALLERGOLOGIE is a prominent academic journal dedicated to the field of immunology and allergy, published by DUSTRI-VERLAG DR KARL FEISTLE in Germany. Since its inception in 1978, the journal has provided a vital platform for researchers, clinicians, and students to disseminate their findings, share insights, and foster advancements in the understanding of allergic diseases and immunological responses. With an ISSN of 0344-5062 and an E-ISSN of the same number, it is a respected source within its category, currently ranked in the 2023 Q4 of the Scopus metrics in immunology and allergy, reflecting its commitment to quality and scholarly rigor. Although not fully open access, ALLERGOLOGIE makes significant contributions to the dialogue on allergy-related topics, encouraging engagement from its readership through a diverse array of articles that span from clinical trials to innovative research methods. This journal continues to be an essential resource for anyone involved in the pursuit of knowledge in allergy and immunology.

Immunological Medicine, published by Taylor & Francis Ltd, is an esteemed open-access journal that has made significant strides in the field of immunology since its establishment in 2018. With an E-ISSN of 2578-5826, the journal has quickly gained recognition for its contribution to advancing immunological research, evidenced by its impressive ranking in the Q2 quartile for both immunology and allergy. Positioned in the United Kingdom, it offers a platform for publishing high-quality original research, reviews, and case studies that delve into the complex interactions of the immune system and its implications for human health. The journal serves as a vital resource for researchers, professionals, and students engaged in the burgeoning fields of immunology, providing open access to a wide audience and fostering collaboration and innovation. With a current Scopus ranking of #81 out of 233 in Immunology and Allergy and #97 out of 236 in Immunology and Microbiology, the journal aims to enhance the visibility and impact of cutting-edge research by bridging the gap between academia and clinical practice.

Allergy Asthma and Clinical Immunology, a pioneering open access journal published by BMC, has been at the forefront of immunological research since its inception in 2005. With an ISSN of 1710-1492, this UK-based journal has established a significant presence in the fields of Immunology, Allergy, and Pulmonary and Respiratory Medicine, achieving notable quartile rankings such as Q2 in Immunology and Allergy in 2023. It plays a crucial role in disseminating high-quality research that advances our understanding of allergy and asthma, making substantial contributions to clinical practices and public health. The journal embraces the principles of Open Access, allowing researchers, professionals, and students from around the globe to access its content freely, thus facilitating knowledge sharing and collaboration within the scientific community. As it converges towards 2024, Allergy Asthma and Clinical Immunology continues to attract impactful studies that drive innovation and improve patient care in the face of rapidly evolving challenges in immunological health.

Allergy Asthma & Respiratory Disease is a pioneering journal dedicated to advancing research and clinical practice in the fields of allergy, asthma, and related respiratory diseases. Published by the esteemed Korean Academy of Asthma Allergy & Clinical Immunology, this journal aims to disseminate high-quality, peer-reviewed articles that contribute to the understanding, diagnosis, and treatment of these prevalent health issues. Although it operates under a subscription model, it maintains a robust reputation for being a pivotal resource in respiratory health, attracting authors and researchers worldwide. The journal emphasizes interdisciplinary approaches and encourages submissions that span from molecular biology to public health perspectives, making it a vital platform for professionals, researchers, and students eager to deepen their knowledge in respiratory medicine. With a commitment to fostering academic discourse in South Korea and beyond, Allergy Asthma & Respiratory Disease is positioned as a significant contributor to the global conversation on respiratory health.

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY is a premier peer-reviewed journal published by Elsevier Science Inc, dedicated to advancing the fields of allergy, asthma, and immunology. With its roots dating back to 1995 and with a focus on high-impact research, this journal has established itself as a leading platform for the dissemination of original research, reviews, and clinical studies within these critical areas. The journal boasts an impressive impact factor, supporting its Q2 ranking in both Immunology and Allergy, as well as in Pulmonary and Respiratory Medicine, indicating its significant contribution to the scientific community. Although it does not currently offer open access options, its comprehensive coverage and rigorous peer-review process ensure that published articles are of the highest quality, making it an invaluable resource for researchers, clinicians, and students alike. The Scopus rankings reflect its esteemed position in the academic landscape, providing professionals with access to cutting-edge developments and insights into the management and treatment of allergic and respiratory conditions.

Postepy Dermatologii i Alergologii is a distinguished Open Access journal published by TERMEDIA PUBLISHING HOUSE LTD, dedicated to advancing the fields of Dermatology and Immunology and Allergy. Since its inception in 2003, this journal has served as a vital platform for researchers and practitioners alike, promoting knowledge sharing and collaboration in Poland and beyond. With a current impact ranking placing it in the Q3 quartile for both Dermatology and Immunology and Allergy categories, it plays a significant role in contributing to academic discourse within these fields. The journal is indexed in Scopus, with respectable rankings reflecting its relevance and quality—#65/142 in Dermatology and #163/233 in Immunology and Allergy. Researchers are encouraged to explore a vast array of innovative studies and reviews, making it an essential resource for anyone seeking to stay at the forefront of dermatological and allergic research. For those interested in discovering groundbreaking findings and contributing to the ongoing dialogue in these disciplines, Postepy Dermatologii i Alergologii offers not only free accessibility but also a commitment to scholarly excellence.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, published by MOSBY-ELSEVIER, stands as a leading peer-reviewed journal dedicated to advancing the understanding of allergies and immunological conditions. With a notable impact factor and a prominent stature in the academic community, it ranks in the Q1 category for both Immunology and Allergy in 2023, reflecting its significance and high citation rates among researchers. Since its establishment in 1963, the journal has fostered scientific discourse and innovation in the field, positioning itself as an essential resource for both seasoned professionals and emerging scholars. The Scopus rankings underscore its influence, being ranked 12th out of 233 in Immunology and Allergy and 15th out of 236 in Immunology and Microbiology, placing it in the top centile of both categories. The journal aims to disseminate cutting-edge research, reviews, and clinical studies that deepen our understanding of allergic diseases and enhance patient care. While not an open access journal, it provides institutions and individuals with opportunities to stay informed on crucial advancements in the immunological sciences.

CLINICAL AND EXPERIMENTAL ALLERGY is a premier peer-reviewed journal dedicated to advancing the scientific understanding of allergy and immunology. Published by Wiley in the United Kingdom, this esteemed journal maintains a significant impact factor, reflecting its high standards and influential research contributions. With an impressive history since its inception in 1971, the journal is poised to continue leading the discourse in the field until at least 2024. It is ranked in the Q2 quartile for both Immunology and Allergy categories, further highlighting its reputable standing within the academic community. The journal's Scopus rankings showcase its academic relevance, securing the 49th and 51st positions in the Medicine and Immunology categories, respectively. Researchers, professionals, and students will find vital insights and contemporary research trends within its pages, making it an essential resource for those invested in understanding and addressing allergic diseases and disorders.

Alergia Astma Immunologia is a dedicated journal focusing on the interdisciplinary fields of immunology and respiratory medicine, published by the Asthma and Allergy Patients Support Organization in Poland. With a commitment to advancing research and sharing knowledge, this journal serves as a platform for scholars and practitioners to discuss critical issues and recent advances in allergy, asthma, and immunological disorders. Despite being in Category Quartiles Q4 for both Immunology and Allergy and Pulmonary and Respiratory Medicine, its importance is highlighted by its continuous publication since 2000, providing a historical perspective on evolving scientific insights. Researchers and clinicians alike benefit from accessing novel findings and case studies that contribute to improved patient outcomes and innovative therapeutic strategies. While the journal currently offers limited open access, its commitment to providing high-quality, peer-reviewed content ensures its relevance in the academic discourse within these vital areas of health science. The journal aims to foster collaboration, stimulate research interest, and promote evidence-based practices within the professional community.